Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …

Cannabidiol (CBD) is one of the main pharmacologically active phytocannabinoids of
Cannabis sativa L. CBD is non-psychoactive but exerts a number of beneficial …

Epilepsy is one of the most common neurological chronic disorders, with an estimated
prevalence of 0. 5–1%. Currently, treatment options for epilepsy are predominantly based on …

Epilepsy is one of the most common serious brain conditions, affecting over 70 million
people worldwide. Its incidence has a bimodal distribution with the highest risk in infants and …

Summary Δ 9-tetrahydrocannabinol (THC) and its sibling, cannabidiol (CBD), are produced
by the same Cannabis plant and have similar chemical structures but differ dramatically in …

Cannabidiol (CBD), a major non-psychoactive phytocannabinoid in cannabis, is an effective
treatment for some forms of epilepsy and pain. At high concentrations, CBD interacts with a …

Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

Glutamate is an essential excitatory neurotransmitter in the central nervous system, playing
an indispensable role in neuronal development and memory formation. The dysregulation of …

Background: Currently, there is a great interest in the potential medical use of cannabidiol
(CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD …

Epilepsy is common in early childhood. In this age group it is associated with high rates of
therapy-resistance, and with cognitive, motor, and behavioural comorbidity. A large number …